In this video, Lukas Delasos, DO, discusses the accelerated approval of zongertinib as an initial treatment option for adults ...
KRAS G12D-targeted protein degrader setidegrasib showed antitumor activity with tolerable safety profile in patients with ...
MedPage Today on MSN
First-in-Class KRAS-Degrader Promising in Pancreatic, Lung Cancers
"There is a clear unmet need for therapies," researcher says ...
Experts review a stage IV NSCLC case, debating whether to delay treatment while awaiting PD-L1 results to ensure a more ...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"), a human-centered global leading research-based ...
In 2025, ESMO Open published 6-year data for the CheckMate 9LA trial, which continued to show overall survival benefits for patients with metastatic non–small cell lung cancer (NSCLC) who had received ...
Four days ahead of its July 7 PDUFA date, the U.S. FDA granted accelerated approval to Dizal (Jiangsu) Pharmaceutical Co. Ltd.’s sunvozertinib (DZD-9008), branded as Zegfrovy, for treating adults with ...
Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine ...
Assessment of Functional Status of Human Leukocyte Antigen Class I Genes in Cancer Tissues in the Context of Personalized Neoantigen Peptide Vaccine Immunotherapy Lymph node metastasis (LNM) ...
Advanced and Metastatic Non-Small Cell Lung Cancer: Cultivating the Habits of Effective Patient Care
Jared Weiss, MD, reveals the lessons taught by a mentor, Dr Corey Langer, in the care of patients with non–small cell lung cancer (NSCLC), extending from the overcoming of "clinical distance" between ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results